Advanced Therapy Medicines Based on Oncolytic Viruses (Part II: Development and Authorisation of IMLYGIC®)
The only oncolytic virus-based product authorised in the US and EU—IMLYGIC®, a genetically modified herpes simplex virus type 1 (by BioVex Inc., a subsidiary of Amgen, Inc.)—was developed and approved for clinical use as monotherapy for recurrent unresectable melanoma. The aim of the study was to an...
Na minha lista:
| Principais autores: | , , |
|---|---|
| 格式: | Artigo |
| 語言: | Russo |
| 出版: |
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)
2021-12-01
|
| 叢編: | Регуляторные исследования и экспертиза лекарственных средств |
| 主題: | |
| 在線閱讀: | https://www.vedomostincesmp.ru/jour/article/view/382 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|